Isavuconazole Versus Voriconazole as the First-line Therapy for Solid Organ Transplant Recipients With Invasive Aspergillosis: Comparative Analysis of 2 Multicenter Cohort Studies

Mario Fernández‐Ruiz; Francesca Gioia; Marta Bodro; Isabel Gutiérrez; Núria Sabé; Regino Rodríguez; Laura Corbella; Teresa López-Viñau; Maricela Valerio; Aitziber Illaro; Sonsoles Salto‐Alejandre; Elisa Cordero; Francisco Arnaíz de las Revillas; María Carmen Fariñas; Patricia Muñóz; Elisa Vidal; Jordi Carratalà; Josune Goikoetxea; António Ramos; Asunción Moreno; Pilar Martín‐Dávila; Jesús Fortün; José María Aguado

doi:10.1097/tp.0000000000005082

Abstract

Isavuconazole (ISA) and voriconazole (VORI) are recommended as the first-line treatment for invasive aspergillosis (IA). Despite theoretical advantages of ISA, both triazole agents have not been compared in solid organ transplant recipients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Fernández‐Ruiz et al. (2024) studied this question.

synapsesocial.com/papers/68e69115b6db6435876184f8 https://doi.org/10.1097/tp.0000000000005082

View at Publisher

Ask AI

Bookmark

Share

Isavuconazole Versus Voriconazole as the First-line Therapy for Solid Organ Transplant Recipients With Invasive Aspergillosis: Comparative Analysis of 2 Multicenter Cohort Studies

Abstract

Discussion

Cite This Study

Isavuconazole Versus Voriconazole as the First-line Therapy for Solid Organ Transplant Recipients With Invasive Aspergillosis: Comparative Analysis of 2 Multicenter Cohort Studies

Abstract

Discussion

Cite This Study

Keep reading

Keep reading